Details of the Drug Combination

General Information of Drug Combination (ID: DCDVLC9)

Drug Combination Name
Lithium Citrate Cycloguanil
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Lithium Citrate   DMXAVX5 Cycloguanil   DMC520D
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 15.69
Bliss Independence Score: 15.69
Loewe Additivity Score: 28.53
LHighest Single Agent (HSA) Score: 28.55

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Lithium Citrate
Disease Entry ICD 11 Status REF
Bipolar disorder 6A60 Approved [2]
Indication(s) of Cycloguanil
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Investigative [3]
Cycloguanil Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Polypeptide deformylase (PDF) TT9SL3Q DEFM_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.